Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Visvikis-Siest S, Siest G. The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clin Chem Lab Med 2008;46:733–47.10.1515/CCLM.2008.178Search in Google Scholar
2. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol 2007;165:1328–35.10.1093/aje/kwm021Search in Google Scholar
3. Dawber T, Meadors G, Moore F. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 1951;41:279–81.10.2105/AJPH.41.3.279Search in Google Scholar
4. Feinleib M, Kannel W, Garrison R, McNamara P, Castelli W. The Framingham Offspring Study. Design and preliminary data. Prev Med 1975;4:518–25.10.1016/0091-7435(75)90037-7Search in Google Scholar
5. Colonna V, Nutile T, Ferrucci RR, Fardella G, Aversano M, Barbujani G, et al. Comparing population structure as inferred from genealogical versus genetic information. Eur J Hum Genet 2009;17:1635–41.10.1038/ejhg.2009.97Search in Google Scholar PubMed PubMed Central
6. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. Cohort profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 2015;44:1172–80.10.1093/ije/dyu229Search in Google Scholar PubMed
7. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, Ntzani EE, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet 2012;44:491–501.10.1038/ng.2249Search in Google Scholar PubMed PubMed Central
8. Mirjanic-Azaric B, Vekic J, Zeljkovic A, Jelic-Ivanovic Z, Djeric M, Milivojac T, et al. Interrelated cathepsin S-lowering and LDL subclass profile improvements induced by atorvastatin in the plasma of stable angina patients. J Atheroscler Thromb 2014;21:868–77.10.5551/jat.21410Search in Google Scholar PubMed
9. Zupan J, van’t Hof RJ, Vindisar F, Haring G, Trebse R, Komadina R, et al. Osteoarthritic versus osteoporotic bone and intra-skeletal variations in normal bone: evaluation with microCT and bone histomorphometry. J Orthop Res 2013;31:1059–66.10.1002/jor.22318Search in Google Scholar PubMed
10. Choi SH, Ruggiero D, Sorice R, Song C, Nutile T, Vernon Smith A, et al. Six novel loci associated with circulating VEGF levels identified by a meta-analysis of genome-wide association studies. PLoS Genet 2016;12:e1005874.10.1371/journal.pgen.1005874Search in Google Scholar PubMed PubMed Central
11. Debette S, Visvikis-Siest S, Chen MH, Ndiaye NC, Song C, Destefano A, et al. Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels. Circ Res 2011;109:554–63.10.1161/CIRCRESAHA.111.243790Search in Google Scholar PubMed PubMed Central
12. Stathopoulou MG, Bonnefond A, Ndiaye NC, Azimi-Nezhad M, El Shamieh S, Saleh A, et al. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J Lipid Res 2012;54:535–41.10.1194/jlr.P030551Search in Google Scholar PubMed PubMed Central
13. Azimi-Nezhad M, Stathopoulou MG, Bonnefond A, Rancier M, Saleh A, Lamont J, et al. Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine 2013;61:602–7.10.1016/j.cyto.2012.10.024Search in Google Scholar PubMed
14. Zaaber I, Rancier M, Stathopoulou MG, Saleh A, Marmouch H, Masson C, et al. Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases. Autoimmunity 2016;49:229–35.10.3109/08916934.2016.1151005Search in Google Scholar PubMed
15. Xie T, Stathopoulou MG, de Andres F, Siest G, Murray H, Martin M, et al. VEGF-related polymorphisms identified by GWAS and risk for major depression. Transl Psychiatry 2017;7:e1055.10.1038/tp.2017.36Search in Google Scholar PubMed PubMed Central
16. Bonnefond A, Saulnier PJ, Stathopoulou MG, Grarup N, Ndiaye NC, Roussel R, et al. What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? PLoS One 2013;8:e55921.10.1371/journal.pone.0055921Search in Google Scholar PubMed PubMed Central
17. Rancier M, Zaaber I, Stathopoulou MG, Chatelin J, Saleh A, Marmouch H, et al. Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases. Autoimmunity 2016;49: 366–72.10.1080/08916934.2016.1199019Search in Google Scholar PubMed
18. Saleh A, Stathopoulou MG, Dade S, Ndiaye NC, Azimi-Nezhad M, Murray H, et al. Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Med Genet 2015;16:90.10.1186/s12881-015-0234-6Search in Google Scholar PubMed PubMed Central
19. Visvikis-Siest S. Association of vascular endothelial growth factor genetic variant with metabolic syndrome, 2014. Patent number: WO2014006231 A1. Available at: http://www.google.com.pg/patents/WO2014006231A1?cl=en&hl=fr. Accessed: 1 June 2017Search in Google Scholar
20. Randox. Identification of genetic variants – VEGF, 2012. Patent number: US20130202587 A1. Available at: https://www.google.com/patents/US20130202587. Accessed: 1 June 2017.Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston
